The influence of metformin and the presence of type 2 diabetes mellitus on mortality and hospitalisation in patients with heart failure.

Background: Metformin is one of the antihyperglycaemic drugs, reducing the risk of major cardiovascular events, including fatal ones. Although it is formally contraindicated in moderate and severe functional stages of heart failure (HF), it is commonly used in patients with concomitant type 2 diabetes mellitus (T2DM).

Aim: We sought to evaluate the effect of metformin and T2DM on total mortality and hospitalisation rates in patients with HF.